L-Deprenyl as an inhibitor of menadione-induced permeability transition in liver mitochondria

Biochemical Pharmacology

Volumn 66, Issue 9, 2003, Pages 1749-1754

  De Marchi, Umberto ^a   Pietrangeli, Paola ^b   Marcocci, Lucia ^b   Mondovì, Bruno ^b   Toninello, Antonio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

L Deprenyl; Menadione; Mitochondria; Permeability transition; Propargylamines; Reactive oxygen species

Indexed keywords

1,4 BENZOQUINONE; AMINE; AROMATIC AMINO ACID; CATION; CYTOCHROME C; MENADIONE; MONOAMINE OXIDASE B INHIBITOR; OXIDIZING AGENT; PYRIDINE NUCLEOTIDE; SELEGILINE;

ACIDITY; ANIMAL CELL; ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; LIVER MITOCHONDRION; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MITOCHONDRION SWELLING; MOLECULAR INTERACTION; NONHUMAN; OXIDATION; PH; PRIORITY JOURNAL; PROTEIN SECRETION; PROTON TRANSPORT; RAT;

EID: 0141957304     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00474-X     Document Type: Article

References (42)

1. Haefely W.E., Kettler R., Keller H.H., Da Prada M. Ro 19-6327, a reversible and highly selective monoamine oxidase B inhibitor: a novel tool to explore the MAO B function in humans. Adv. Neurol. 53:1990;505-512.
2. Tetrud J.W., Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 245:1989;519-522.
3. Tatton W.G., Greenwood C.E. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30:1991;666-672.
4. Tariot P.N., Cohen R.M., Sunderland T., Newhouse P.A., Yount D., Mellow A.M., Weingartner H., Mueller E.A., Murphy D.L. L-Deprenyl in Alzheimer's disease. Preliminary evidence for behavioural change with monoamine oxidase B inhibition. Arch. Gen. Psychiatry. 44:1987;427-433.
5. Knoll J. Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases. Med. Res. Rev. 12:1992;505-524.
6. Ansari K.S., Yu P.H., Kruck T.P., Tatton W.G. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J. Neurosci. 13:1993;4042-4053.
7. Buys Y.M., Trope G.E., Tatton W.G. (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr. Eye Res. 14:1995;119-126.
8. Salo P.T., Tatton W.G. Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res. 31:1992;394-400.
9. Wadia J.S., Chalmers-Redman R.M., Ju W.J., Carlile G.W., Phillips J.L., Fraser A.D., Tatton W.G. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J. Neurosci. 18:1998;932-947.
10. + toxicity by deprenyl (selegiline). Ann. N.Y. Acad. Sci. 738:1994;214-221.
11. Seniuk N.A., Henderson J.T., Tatton W.G., Roder J.C. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl. J. Neurosci. Res. 37:1994;278-286.
12. Cohen G. Monoamine oxidase, hydrogen peroxide and Parkinson's disease. Adv. Neurol. 45:1987;119-125.
13. Gerlach M., Desser H., Youdim M.B., Riederer P. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. J. Neural Transm. Suppl. 48:1996;7-21.
14. Tatton W.G., Ju W.Y., Holland D.P., Tai C., Kwan M. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63:1994;1572-1575.
15. Fang J., Zuo D.M., Yu P.H. Lack of protective effect of R(-)-deprenyl on programmed cell death of mouse thymocytes induced by dexamethasone. Life Sci. 57:1995;15-22.
16. Kitani K., Minami C., Isobe K., Maehara K., Kanai S., Ivy G.O., Carrillo M.C. Why (-)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech. Ageing Dev. 123:2002;1087-1100.
17. Xu L., Ma J., Seigel G.M., Ma J.X. L-Deprenyl blocking apoptosis and regulating gene expression in cultured retinal neurons. Biochem. Pharmacol. 58:1999;1183.D-1190.D.
18. Tatton W.G., Chalmers-Redman R.M. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 47:1996;S171-S183.
19. Szende B., Bokonyi G., Bocsi J., Keri G., Timar F., Magyar K. Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites. J. Neural Transm. 108:2001;25-33.
20. Lee C.S., Lee C.S., Ko H.H., Song J.H., Han E.S. Effect of R-(-) -deprenyl and harmaline on dopamine- and peroxynitrite-induced membrane permeability transition in brain mitochondria. Neurochem. Res. 27:2002;215-224.
21. Zoratti M., Szabò I. The mitochondrial permeability transition. Biochim. Biophys. Acta. 1241:1995;139-176.
22. Olanov C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22:1999;123-144.
23. Ames B.N. Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science. 221:1983;1256-1264.
24. Moore H.W., Czerniak R. Naturally occurring quinones as potential bioreductive alkylating agents. Med. Res. Rev. 1:1981;249-280.
25. Sawahata T., Neal R.A. Biotransformation of phenol to hydroquinone and catechol by rat liver microsomes. Mol. Pharmacol. 23:1983;453-460.
26. Frei B., Winterhalter K.H., Richter C. Menadione-(2-methyl-1,4-naphthoquinone) dependent enzymatic redox cycling and calcium release by mitochondria. Biochemistry. 25:1986;4438-4443.
27. Schneider W.C., Hogeboom G.H. Intracellular distribution of enzymes. V. Further studies on the distribution of cytochrome c in rat homogenate. J. Biol. Chem. 183:1950;123-128.
28. Gornall A.G., Bardawill C.J., David M.M. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem. 177:1949;751-766.
29. Kamo N., Muratsugu M., Hongoh R., Kabatake Y. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenylphosphonium and relationship between proton electrochemical potential and phosphorylation potential in steady-state. J. Membr. Biol. 49:1979;105-121.
30. Susin S.A., Zamzami N., Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim. Biophys. Acta. 1366:1998;151-165.
31. 2+-induced mitochondrial membrane permeabilization: role of coenzyme Q redox state. Am. J. Physiol. 269:1995;C141-C147.
32. Kappus H., Sies H. Toxic drug effects associated with oxygen metabolism: redox cycling and lipid peroxidation. Experientia. 37:1981;1233-1241.
33. Bernardi P. The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death. Biochim. Biophys. Acta. 1275:1996;5-9.
34. Costantini P., Chernyak B.V., Petronilli V., Bernardi P. Selective inhibition of the mitochondrial permeability transition pore at the oxidation-reduction sensitive dithiol by monobromobimane. FEBS Lett. 362:1995;239-242.
35. Marcocci L., De Marchi U., Salvi M., Milella Z.G., Nocera S., Agostinelli E., Mondovi B., Toninello A. Tyramine and monoamine oxidase inhibitors as modulators of the mitochondrial membrane permeability transition. J. Membr. Biol. 188:2002;23-31.
36. + channels in alloimmune effector cell lytic function. Immunopharmacol. Immunotoxicol. 11:1989;165-178.
37. Pearson W.L., Nichols C.G. Block of the Kir2.1 channel pore by alkylamine analogues of endogenous polyamines. J. Gen. Physiol. 112:1998;351-363.
38. + channels in pituitary tumor cells (GH3). J. Membr. Biol. 140:1994;133-142.
39. 2+-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem. J. 268:1990;153-160.
40. Dougherty D.A. Cation-π interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Science. 271:1996;163-168.
41. + channels in rabbit atrial myocytes. Intracellular substance-mediated mechanism of inward rectification. J. Biol. Chem. 270:1995;9289-9294.
42. 2+ and phosphate movements. FEBS Lett. 142:1982;63-66.